Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
Research & Development - Product Approvals
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Swifter market access for drugs will require a revolution
11 March 2010
The plenary session at the Drug Information Association’s Euromeeting in Monaco this week took the curious form of an enforced debate on pharmaceutical R&D productivity between representatives from the industry and regulatory authorities. The motion ...
FDA panel backs InterMune's pulmonary fibrosis drug Esbriet despite reservations
10 March 2010
By a decisive 9-3 vote, the US FDA 's advisory committee on pulmonary drugs on March 9th recommended that the agency approve the new drug application (NDA) from InterMune to market as a treatment its drug Esbriet (pirfenidone) to reduce the decline ...
Japanese recommendation moves alogliptin closer to the market
04 March 2010
An advisory committee to Japan's ministry of health, labour and welfare has recommended for approval Takeda 's oral antidiabetic, alogliptin. The positive opinion moves the DPP-4 inhibitor closer to what is likely to be its first market, following ...
FDA panel recommends BMS's belatacept for kidney transplant rejection
02 March 2010
By a 13-to-5 vote, the US FDA 's advisory committee on cardiovascular and renal drugs on March 1st recommended that the agency grant Bristol-Myers Squibb 's biologics licence application for belatacept, to be used to prevent rejection of ...
Vectibix recommended for colorectal cancer in Japan
26 February 2010
Takeda has received an approval recommendation in Japan for its EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), for the treatment of colorectal cancer. The product, submitted in June 2008, was the subject of a positive opinion from ...
 
Market Insight - Fear gives way to prudence as VCs eye return of bull biotech market
19 February 2010
2009 was a bad year for investment in the biotech sector, with venture capital funds fleeing to safer havens and many small firms struggling to get enough financing to keep their R&D projects afloat. ...
Market Insight - Microdosing reaching a tipping point?
05 February 2010
Advocates of microdosing, a technique that involves testing very small doses of products in humans, think it will improve the efficiency of drug development by flagging at an early stage those ...
Market Insight - Downturn leaves HIV/AIDS funds feeling the pinch
09 February 2010
The global economic crisis has had a significant negative impact on all areas of life, including labour and property markets, national banking systems and the prices of consumer goods. With so many ...
 
Face to face: Ex-Novartis manager takes two-step approach to women's health at Lumavita
12 January 2010
Many pharmaceutical and biotech companies devote themselves to the discovery and development of novel drugs for unmet medical needs. However, with R&D costs and regulatory hurdles multiplying, and ...
Anti-obesity drugs: an inventor's perspective
20 November 2009
After years of anti-obesity disappointments, Orexigen's Contrave, Vivus's Qnexa and Arena's lorcaserin stand on the verge of being filed with the US FDA. Professor Michael Cowley, inventor of ...
Face-to-Face: Asia-Pacific emerging as the clinical trial hotspot
07 October 2009
Six out of the top 10 emerging markets in the world to conduct clinical trials are now in the Asia-Pacific region, Albert Liou, general manager of this region for biopharmaceutical services firm ...
 
European Medicines Agency and logos: snakes, DNA and the pestle and mortar
22 December 2009
Logos are said to be an important part of an organisation's branding. Really good logos contribute to an organisation's visibility, credibility and memorability, so say branding experts. The logo of ...
Pfizer's fine: a revisit of self-regulation
10 September 2009
The US is a great place to do business. Being an almost free market, the profits are good, but so also are the temptations. So if you can't be bothered to put the money into a clinical trial to find ...
Commentary - EC final report: bark worse than bite?
23 July 2009
On July 8th, 2009, the European Commission reported on its 18-month inquiry into competition in the pharmaceuticals sector. Bill Batchelor of Baker & McKenzie 's Brussels antitrust practice ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm